<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01045577</url>
  </required_header>
  <id_info>
    <org_study_id>AB04029</org_study_id>
    <nct_id>NCT01045577</nct_id>
  </id_info>
  <brief_title>A Double-blind, Placebo-controlled, Randomized, Parallel-group Study to Evaluate the Activity of Oral AB1010 in Adults Patients With Moderate to Severe Chronic Plaque Psoriasis</brief_title>
  <official_title>A Double-blind, Placebo-controlled, Randomized, Parallel-group Study to Evaluate the Activity of Oral AB1010 in Adults Patients With Moderate to Severe Chronic Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AB Science</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AB Science</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A double-blind, placebo-controlled, randomized, parallel-group study to evaluate the activity
      of oral AB1010 in adults patients with moderate to severe chronic plaque psoriasis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the activity of oral AB1010, administered at two dose levels during 12 weeks to
      patients with moderate to severe chronic plaque psoriasis, assessed on :

      i)Body Surface Area (BSA), Psoriasis Area and Severity Index (PASI), Overall Lesion Severity
      (OLS), Physician's Global Assessment (PGA) and Patient's Global Psoriasis Assessment (PGPA)
      ii)clinical and biological safety parameters iii) pharmacokinetic profile of AB1010
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">January 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in BSA after 12 weeks of treatment</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage change from baseline in PASI score, proportion of patients reaching a 90%, 75% or 50% improvement in PASI score after 12 weeks of treatment; time to and duration of first occurrence in PASI 50, 75 and 90</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving an OLS rating of Minimal or Clear after 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change from baseline in PGA and PGPA after 12 weeks of treatment</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Masitinib (AB1010)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Masitinib (AB1010)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo mactching masitinib</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo matching masitinib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Masitinib</intervention_name>
    <description>6 mg/kg/day</description>
    <arm_group_label>Masitinib (AB1010)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Masitinib</intervention_name>
    <description>3 mg/kg/day</description>
    <arm_group_label>Masitinib (AB1010)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching masitinib (3 mg/kg/day and 6 mg/kg/day)</description>
    <arm_group_label>Placebo mactching masitinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female outpatients aged 18 to 75 years with chronic plaque psoriasis

          -  Plaque psoriasis covering ≥ 10% BSA

          -  Disease duration ≥ 6 months

          -  PASI ≥ 12.0 at screening

        Exclusion Criteria:

          -  Guttate, erythrodermic or pustular psoriasis as sole or predominant form of the
             disease

          -  Clinically significant psoriasis flare during screening or at time of enrollment

          -  Systemic therapy for psoriasis or systemic immunosuppressive therapy for other
             indications within 28 days prior to enrollment

          -  Topical treatment for psoriasis within 14 days prior to enrollment

          -  Use of CYP3A4 moderate and strong inhibitors within 4 weeks prior to randomization

          -  Active current bacterial, viral (including hepatitis B and C, HIV, EBV, CMV, herpes
             zoster, herpes simplex), fungal, mycobacterium, protozoan, or other infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Paul ORTONNE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Nice</affiliation>
  </overall_official>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2010</study_first_submitted>
  <study_first_submitted_qc>January 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2010</study_first_posted>
  <last_update_submitted>January 8, 2010</last_update_submitted>
  <last_update_submitted_qc>January 8, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2010</last_update_posted>
  <responsible_party>
    <name_title>Alain MOUSSY</name_title>
    <organization>AB Science</organization>
  </responsible_party>
  <keyword>Severe Psoriasis</keyword>
  <keyword>Kinase Inhibitor</keyword>
  <keyword>Masitinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

